secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quince Therapeutics, Inc. (QNCX)
CIK:        0001662774
Form:       8-K
Filed at:   2023-01-27T23:59:59+00:00
Accession:  0001193125-23-017549
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Quince Therapeutics sells protease inhibitor portfolio to Lighthouse Pharma for up to $150M milestones
--------------------------------------------------------------------------------

- Received 7.5% of Lighthouse common stock; eligible for up to $150M in milestone payments.
- Royalties: high single-digit to mid-teens on clinical-stage programs; low single-digit on preclinical.
- Exclusive option to obtain rights to COR388 for animal health until June 30, 2023.
- No salary increases for 2023; executives granted stock options: CEO 600k, others 110k-225k, vesting monthly over 4 years.
- 2022 bonus payouts: CEO $169,287, CAO $137,185, CMO $116,962, CBO $104,650.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662774/000119312523017549/0001193125-23-017549-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662774/000119312523017549/d453314d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-017549

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer